Duchenne muscular dystrophy: Issues in expanding newborn screening

Current Opinion in Pediatrics

Volumn 19, Issue 6, 2007, Pages 700-704

  Kemper, Alex R ^a,c   Wake, Melissa A ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c North Pavilion   (United States)

Author keywords

Duchenne; Health policy; Muscular dystrophy; Neonatal screening

Indexed keywords

AMINO ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CORTICOSTEROID;

COST BENEFIT ANALYSIS; DUCHENNE MUSCULAR DYSTROPHY; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; GENE THERAPY; HUMAN; MUSCLE STRENGTH; NEWBORN SCREENING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; STEM CELL TRANSPLANTATION; VITAMIN SUPPLEMENTATION;

COST-BENEFIT ANALYSIS; HUMANS; INFANT, NEWBORN; MUSCULAR DYSTROPHY, DUCHENNE; NEONATAL SCREENING; PREDICTIVE VALUE OF TESTS;

EID: 36349015997     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3282f19f65     Document Type: Review

References (43)

1. Davies SC, Cronin E, Gill M, et al. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol Assess 2000;4:i-v, 1-99.
2. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001;108:972-982.
3. Wilson JMG, Jungner F. Principles and practice of screening for disease. Public Health Paper No. 34. Geneva, Switzerland: World Health Organization; 1968.
4. Elliman DAC, Dezateux C, Bedford HE. Newborn and childhood screening programmes: criteria, evidence, and current policy. Arch Dis Child 2002;87:6-9.
5. Ross LF. Screening for conditions that do not meet the Wilson and Jungner criteria: the case of Duchenne muscular dystrophy. Am J Med Genet A 2006;140:914-922. This up-to-date expert review evaluates DMD screening using an ethical framework for analysis. The author provides important insights into the role of informed consent, whether girls should be screened, and the relative merits of screening prenatally, in newborns, or later in infancy.
6. American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system: executive summary. Pediatrics 2006;117 (5 Pt 2):S296-S307. This is a summary of current US newborn screening policy.
7. Laird L, Dezateux C, Anionwu EN. Neonatal screening for sickle cell disorders: what about the carrier infants? BMJ 1996; 313:407-411.
8. Alexander D, van Dyck PC. A vision of the future of newborn screening. Pediatrics 2006; 117:S350-S354. In this editorial, the authors explore the rationale for screening for 'untreatable' conditions.
9. Taylor HA, Wilfond BS. Ethical issues in newborn screening research: lessons from the Wisconsin cystic fibrosis trial. J Pediatr 2004; 145:292-296.
10. Bailey DB, Skinner D, Warren SF. Newborn screening for developmental disabilities: reframing presumptive benefit. Am J Public Health 2005; 95:1889-1893.
11. Mischler EH, Wilfond BS, Fost N, et al. Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. Pediatrics 1998; 102:44-52.
12. Karmiloff-Smith A, Scerif G, Thomas M. Different approaches to relating genotype to phenotype in developmental disorders. Dev Psychobiol 2002; 40:311-322.
13. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000; 67:117-133.
14. Ross LF. Minimizing risks: the ethics of predictive diabetes mellitus screening research in newborns. Arch Pediatr Adolesc Med 2003; 157:89-95.
15. Tarini BA, Christakis DA, Welch HG. State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results. Pediatrics 2006; 118:448-456. This is a model of the number of expected false-positive screening results as screening expands.
16. Thomasgard M, Metz WP. The vulnerable child syndrome revisited. J Dev Behav Pediatr 1995; 16:47-53.
17. Botkin JR, Clayton EW, Fost NC, et al. Newborn screening technology: proceed with caution. Pediatrics 2006; 177:1793-1799. This well reasoned editorial describes the potential risks of newborn screening and provides recommendations for how newborn screening policy decisions should be made.
18. Wald N. Neonatal screening: old dogma or sound principle? Pediatrics 2007; 119:406-407. This letter to the editor refutes some of the rationale of Alexander and van Dyck [8•] regarding the potential benefit of screening for 'untreatable' conditions.
19. Campbell E, Ross LF. Parental attitudes regarding newborn screening of PKU and DMD. Am J Med Genet A 2003; 120:209-214.
20. Guirguis-Blake J, Calonge E, Miller T, et al. Current Processes of the U.S. Preventive Services Task Force: refining evidence-based recommendation development. Ann Intern Med 2007; 147:117-122.
21. Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002; 12:926-929.
22. Online Mendelian Inheritance in Man. #310200. Muscular dystrophy, Duchenne type; DMD. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=310200. [Accessed 19 July 2007] This website provides thorough and continuously updated information about the natural history and treatment of DMD.
23. Anderson JL, Head SI, Rae C, Morley JW. Brain function in Duchenne muscular dystrophy. Brain 2002; 125:4-13.
24. Stockley TL, Akber S, Bulgin N, Ray PN. Strategy for comprehensive molecular testing for Duchenne and Becker muscular dystrophies. Genet Test 2006; 10:229-243.
25. Becker K, Robb SA, Hatton Z, et al. Loss of a single amino acid from dystrophin resulting in Duchenne muscular dystrophy with retention of dystrophin protein. Hum Mutat 2003; 21:651.
26. Jeppesen J, Green A, Steffensen BF, Rahbek J. The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscul Disord 2003; 13:804-812.
27. Nigro G, Comi LI, Limongelli FM, et al. Prospective study of X-linked progressive muscular dystrophy in Campania. Muscle Nerve 1983; 6:253-262.
28. Bushby KMD, Hill A, Steele JG. Failure of early diagnosis in symptomatic Duchenne muscular dystrophy. Lancet 1999; 353:557-558.
29. Pescatori M, Broccolini A, Minetti C, et al. Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J 2007; 21:1210-1226.
30. Hoogerwaard EM, Bakker E, Ippel PF, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 1999; 353:2116-2119.
31. Escolar DM, Buyse G, Henricson E, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 2005; 58:151-155.
32. Moxley RT, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64:13-20.
33. Radley HG, DeLuca A, Lynch GS, Grounds MD. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. Int J Biochem Cell Biol 2007; 39:469-477.
34. Foster K, Foster H, Dickson JG. Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 2006; 13:1677-1685.
35. Grounds MD, Davies KE. The allure of stem cell therapy for muscular dystrophy. Neuromuscul Disord 2007; 17:206-208.
36. Zellweger H, Antonik A. Newborn screening for Duchenne muscular dystrophy. Pediatrics 1975; 55:30-34.
37. Bradley DM, Parsons EP, Clarke AJ. Experience with screening newborns for Duchenne muscular dystrophy in Wales. BMJ 1993; 306:357-360.
38. Drousiotous A, Ioannou P, Georgious T, et al. Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test 1998; 2:55-60.
39. Scheuerbrandt G, Lundin A, Lovgren T, Mortier W. Screening for Duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program. Muscle Nerve 1986; 9:11-23.
40. Parsons EP, Clarke AJ, Hood K, et al. Newborn screening for Duchenne muscular dystrophy: a psychosocial study. Arch Dis Child Fetal Neonatal Ed 2002; 86:F91-F95.
41. Hildes E, Jacobs HK, Cameron A, et al. Impact of genetic counseling after neonatal screening for Duchenne muscular dystrophy. J Med Genet 1993; 30:670-676.
42. Rosenberg T, Jacobs HK, Thompson R, Horne JM. Cost-effectiveness of neonatal screening for Duchenne muscular dystrophy - How does this compare to existing neonatal screening for metabolic disorders? Soc Sci Med 1993; 37:541-547.
43. Centers for Disease Control and Prevention. What is CDC doing about DBMD? http://www.cdc.gov/ncbddd/duchenne/cdc.htm. [Accessed 19 July 2007]